Company Description
Aclarion, Inc. operates as a healthcare technology company in the United States.
The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments.
It develops NOCISCAN software application, a non-invasively analyze the chemical makeup of intervertebral discs in the spine.
The company also develops NOCISCAN Post-Processor Suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021.
Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
| Country | United States |
| Founded | 2008 |
| IPO Date | Apr 22, 2022 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Brent Ness |
Contact Details
Address: 8181 Arista Place, Suite 100 Broomfield, Colorado 80021 United States | |
| Phone | 833 275 2266 |
| Website | aclarion.com |
Stock Details
| Ticker Symbol | ACON |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.35 |
| CIK Code | 0001635077 |
| CUSIP Number | 655187409 |
| ISIN Number | US6551872012 |
| Employer ID | 47-3324725 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Brent Ness | Chief Executive Officer, President and Director |
| Dr. Jeffrey John Thramann M.D. | Executive Chairman |
| John Lorbiecki | Chief Financial Officer |
| Ryan Bond | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 23, 2025 | 8-K | Current Report |
| Apr 9, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |